Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data - Summary - MDSpire

Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data

  • By

  • Soheila Aghlmandi

  • Kurt Schmidlin

  • Carola Huber

  • Pascal Godet

  • Katharina Kusejko

  • Marcel Stoeckle

  • Matthias Cavassini

  • Huldrych F Günthard

  • Enos Bernasconi

  • Alexandra Calmy

  • Patrick Schmid

  • Cornelia Staehelin

  • Niklaus D Labhardt

  • Heiner C Bucher

  • Swiss HIV Cohort Study

  • I Abela

  • K Aebi-Popp

  • A Anagnostopoulos

  • M Battegay

  • E Bernasconi

  • D L Braun

  • H C Bucher

  • A Calmy

  • M Cavassini

  • A Ciuffi

  • G Dollenmaier

  • M Egger

  • L Elzi

  • J Fehr

  • J Fellay

  • H Furrer

  • C A Fux

  • H F Günthard

  • A Hachfeld

  • D Haerry

  • B Hasse

  • H H Hirsch

  • M Hoffmann

  • I Hösli

  • M Huber

  • C R Kahlert

  • L Kaiser

  • O Keiser

  • T Klimkait

  • R D Kouyos

  • H Kovari

  • K Kusejko

  • G Martinetti

  • B Martinez de Tejada

  • C Marzolini

  • K J Metzner

  • N Müller

  • J Nemeth

  • D Nicca

  • P Paioni

  • G Pantaleo

  • M Perreau

  • A Rauch

  • P Schmid

  • R Speck

  • M Stöckle

  • P Tarr

  • A Trkola

  • G Wandeler

  • S Yerly

  • July 16, 2025

  • 0 min

Share

Objective:

To analyze healthcare costs related to HIV management and the impact of direct-acting agents (DAAs) for hepatitis C treatment in Switzerland from 2012 to 2017, focusing on trends and drivers of costs.

Key Findings:
  • Mean adjusted annual overall cost in 2012 was CHF 24,713, increasing to CHF 24,881 in 2017, indicating a slight upward trend in healthcare costs.
  • Costs for ART decreased over time, while hospitalization costs increased by 7.2% from CHF 8,727 in 2012 to CHF 9,406 in 2017, highlighting a shift in cost distribution.
  • Mean costs for DAAs for 171 PWH coinfected with HCV were CHF 52,647, representing a 9.4% increase, suggesting a significant financial burden despite their effectiveness.
Interpretation:

Overall cost increases for PWH in Switzerland from 2012 to 2017 were minimal, with DAAs contributing marginally to total costs despite their high individual costs, indicating a need for careful cost management.

Limitations:
  • Lack of unique patient identifiers and diagnostic codes in claims data complicates detailed cost analyses, potentially affecting the accuracy of findings.
  • The study only includes data from two health insurers, potentially limiting generalizability to the broader Swiss population.
Conclusion:

The study highlights the need for comprehensive data on healthcare costs and the impact of innovative treatments in managing HIV and HCV coinfection, suggesting future research should explore broader datasets and additional cost factors.

Original Source(s)

Trends in Costs for HIV Care During a Hepatitis C Virus Early Treatment and Elimination Program: A Data Linkage Study of Claims and Swiss HIV Cohort Study Data

  • by Soheila Aghlmandi, Kurt Schmidlin, Carola Huber, Pascal Godet, Katharina Kusejko, Marcel Stoeckle, Matthias Cavassini, Huldrych F Günthard, Enos Bernasconi, Alexandra Calmy, Patrick Schmid, Cornelia Staehelin, Niklaus D Labhardt, Heiner C Bucher, Swiss HIV Cohort Study, I Abela, K Aebi-Popp, A Anagnostopoulos, M Battegay, E Bernasconi, D L Braun, H C Bucher, A Calmy, M Cavassini, A Ciuffi, G Dollenmaier, M Egger, L Elzi, J Fehr, J Fellay, H Furrer, C A Fux, H F Günthard, A Hachfeld, D Haerry, B Hasse, H H Hirsch, M Hoffmann, I Hösli, M Huber, C R Kahlert, L Kaiser, O Keiser, T Klimkait, R D Kouyos, H Kovari, K Kusejko, G Martinetti, B Martinez de Tejada, C Marzolini, K J Metzner, N Müller, J Nemeth, D Nicca, P Paioni, G Pantaleo, M Perreau, A Rauch, P Schmid, R Speck, M Stöckle, P Tarr, A Trkola, G Wandeler, S Yerly

  • July 16, 2025

Related Content

Marked Reduction in HIV/HCV Coinfections in Iceland Following the TraP HepC Nationwide Hepatitis C Elimination Program

Hepatitis C Co-infection Among Pregnant Women With Syphilis in West Virginia, 2019–2023

The Loan Cap That Could Shrink the Doctor Pipeline

New federal limits on medical school borrowing may quietly reshape who becomes a physician—and where they practice.